E-resources
-
Fabiani, Claudia; Vitale, Antonio; Emmi, Giacomo; Sgheri, Arianna; Lopalco, Giuseppe; Sota, Jurgen; Guerriero, Silvana; Iannone, Florenzo; Frediani, Bruno; Vannozzi, Lorenzo; Bianco, Maria Teresa; Giovannini, Valtere; Tosi, Gian Marco; Cantarini, Luca
Frontiers in pharmacology, 12/2019, Volume: 10Journal Article
Recent expiry of patents for tumor necrosis factor (TNF)-α inhibitors has led to the employment of biosimilars in clinical practice. The aim of the study was to identify any change in the control of ocular inflammatory manifestations among patients with non-infectious uveitis switching from an originator to a corresponding anti-TNF-α biosimilar. Thirty-seven consecutive patients (62 eyes involved) with non-infectious uveitis undergoing the switch from anti-TNF-α originators to biosimilars were retrospectively enrolled; the frequency of ocular flares before and after the switch as well as best corrected visual acuity (BCVA), central macular thickness (CMT), daily systemic corticosteroid intake, and frequency of uveitic macular edema (UME) at the switch and at the following assessments were statistically analysed. The number of ocular flares during the 12 months preceding the switch was 16, corresponding to 3.6 flares/100 patients/12 months; the number of flares after the switch was 14, corresponding to 2.0 flares/100 patients/12 months. No statistically significant differences were identified in the frequency of flares ( = 0.84) and in the number of patients experiencing ocular flares ( = 0.39) between the twelve months preceding the switch and the period thereafter. No statistically significant changes were observed in the BCVA ( = 0.27), CMT ( = 0.50), frequency of UME ( = 0.57) and daily corticosteroid intake ( = 0.42) between the time of the switch and the last follow-up visit. The switch to biosimilars represents a feasible treatment choice associated with the maintenance of clinical efficacy in patients with non-infectious uveitis previously treated with the corresponding originator anti-TNF-α biologic agents.
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.